Clinical Trials Sponsored by Janssen Pharmaceutica

Total 22138 results

Janssen Pharmaceutical K.K.

Completed

A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection

Mycoses | Candidiasis | Neutropenia | Aspergillosis | Cryptococcosis | Histoplasmosis | Blastomycosis

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain

Pain | Cancer

Japan
Janssen Pharmaceutical K.K.

Completed

A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia

Schizophrenia

Japan
Janssen Pharmaceutical K.K.

Completed

Continuous Treatment Study of Topiramate in Migraine Participants

Migraine

Japan
Janssen Pharmaceutical K.K.

Completed

A Phase 4 Study to Evaluate Pharmacokinetics and Safety of Darunavir Along With Ritonavir in Healthy Male Japanese Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ 10229570-AAA to Evaluate Safety and Tolerability in Japanese Participants With Acne Vulgaris

Acne Vulgaris

Japan
Janssen Pharmaceutical K.K.

Completed

A Long-Term Study of JNS007ER in Patients With Schizophrenia

Schizophrenia
Janssen Pharmaceutical K.K.

Completed

An Exploratory Study of Tramadol Hydrochloride in Patients With Osteoarthritis of the Knee or Low Back Pain

Osteoarthritis | Low Back Pain
Janssen Pharmaceutical K.K.

Completed

A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia

Schizophrenia
Janssen Pharmaceutical K.K.

Completed

A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients

Schizophrenia
Janssen Pharmaceutical K.K.

Recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Generalized Pustular Psoriasis | Erythrodermic Psoriasis

Japan
Janssen Pharmaceutical K.K.

Recruiting

A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa

X-Linked Retinitis Pigmentosa

Japan
Janssen Pharmaceutical K.K.

Recruiting

A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Japan
Janssen Pharmaceutical K.K.

Recruiting

An Observational Study of Japanese Participants With X-linked Retinitis Pigmentosa

X-Linked Retinitis Pigmentosa

Japan
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of Guselkumab in Participants With Systemic Sclerosis

Scleroderma, Systemic

Japan
Janssen Pharmaceutical K.K.

Terminated

A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants

Respiratory Syncytial Virus Prevention

Japan
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Crohns Disease

Japan
Janssen Pharmaceutical K.K.

Active, not recruiting

A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

Prostatic Neoplasms

Japan
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

Waldenstrom Macroglobulinemia

Japan
Janssen Pharmaceutical K.K.

Terminated

A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer

Stomach Neoplasms | Esophageal Neoplasms

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers

Neoplasm

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression

Depression

Japan
Janssen Pharmaceutical K.K.

Completed

An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)

Tuberculosis, Multidrug-Resistant

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive

Hepatitis C, Chronic

Japan
Janssen Pharmaceutical K.K.

Withdrawn

A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR8020 in Japanese Healthy Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injection of JNJ-64304500 in Healthy Japanese and Caucasian Male Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

Japan
Janssen Pharmaceutical K.K.

Completed

Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Lymphoma, Mantle-cell

Japan
Janssen Pharmaceutical K.K.

Completed

Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration in Healthy Japanese Adult Male Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants

Respiratory Syncytial Virus Infections

Japan
Janssen Pharmaceutical K.K.

Completed

A Comparative Study of JNS013 in Participants With Post-Tooth-Extraction Pain

Pain | Postoperative Pain

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis

Dermatitis, Atopic

Japan
Janssen Pharmaceutical K.K.

Completed

A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis

Psoriasis

Japan
Janssen Pharmaceutical K.K.

Terminated

A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients (DRAGON)

Hepatitis C, Chronic

Japan
Janssen Pharmaceutical K.K.

Completed

A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients

Hepatitis C, Chronic

Japan
Janssen Pharmaceutical K.K.

Completed

A Phase 2 Study of Tapentadol Extended-Release (JNS024ER) ) in Japanese Participants With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia

Pain | Diabetic Neuropathies | Neuralgia | Postherpetic Neuralgia

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)

Multiple Myeloma

Japan
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of Acetaminophen Plus Tramadol Hydrochloride (JNS013) in Participants With Chronic Pain

Pain

Japan
Janssen Pharmaceutical K.K.

Completed

A Dose-Finding Study of Topiramate (JNS019) in Participants With Migraine

Migraine

Japan
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia

Schizophrenia

Taiwan, Japan, Korea, Republic of
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.

Alzheimer Disease
Janssen Pharmaceutical K.K.

Completed

An Exploratory Study on the Safety and Effectiveness of Paliperidone in Patients With Schizophrenia

Schizophrenia
Janssen Pharmaceutical K.K.

Completed

Phase II Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Cancer Pain- Assessment of Effectiveness, Safety and Pharmacokinetics -

Pain, Intractable

3

Subscribe